Vendor Intelligence Report: Glamgurcraft Innovations Foreign Trade

Executive summary

Across 1 Finnrick lab test, Glamgurcraft's overall pass rate is 100% (1 pass / 0 fail). The positive signal is real but extremely narrow: it is a single Tirzepatide result from July 2025, not a catalog-wide pattern. For buyers evaluating Tirzepatide only, this keeps Glamgurcraft from being a simple write-off; for Semaglutide, Retatrutide, Cagrilintide and the rest of the archived catalog, the report finds no Finnrick product-quality baseline.

The non-lab file is less reassuring. Glamgurcraft's canonical domain now returns NXDOMAIN, with no successor domain or authenticated channel identified; archive and certificate history point to a short public storefront window rather than a durable public brand. Hong Kong formation records, archived branding, and a twelve-plus-year manufacturer narrative do not line up cleanly.

The address trail carries the highest-severity off-product issue. The same Hong Kong room appears in Glamgurcraft records and in active OFAC entries for other entities; the report is careful that Glamgurcraft itself is not shown as designated, but the co-address creates real payment, procurement, and compliance-screening exposure. An Instagram promotion adds an unverified Alibaba-supplier claim and a UK forwarding-label clue that complicates origin assumptions.

This is not a report about a hated vendor with a complaint avalanche; it is about a vendor with almost no observable market history, weak authentication controls, an unlabeled-vial chain-of-custody note, non-reversible payment rails, and a single lab pass. If Glamgurcraft resurfaces, the practical question is continuity: whether the seller can prove the same legal entity, channel, batch, and custody trail before funds move.

Inside the full report:

• Appendix A — Finnrick Laboratory Data, including the complete Tirzepatide record and methodology-sensitivity view
• Dated operating timeline built from Hong Kong registry, Wayback, DNS, and Certificate Transparency artifacts
• Corporate-identity analysis comparing registry name, archived storefront branding, footer wording, and contact rails
• Room 511 co-address map with OFAC sanctions-proximity evidence and Joscur/One-Peptides commercial lead
• Archived Xunrui CMS storefront, catalog, FAQ payment rails, and verification-control review
• Instagram promotion and logistics trail, including Alibaba-claim and UK forwarding-label exhibits

Risk assessment

• Operational-continuity and authentication risk — high: glamgurcraft.com remains NXDOMAIN; no current authenticated storefront, official channel list, successor domain, or authorized-reseller list was identified.
• Corporate-transparency and unsupported-history risk — high: Hong Kong entity dates to May 2024 while the site claimed over twelve years; branding was inconsistent and directors/beneficial owners were not identified in free sources.
• Sanctions-proximity / counterparty-compliance risk — high: Room 511 is shared with active OFAC-designated Yonghongan Trade Limited and Canes Venatici Limited; Glamgurcraft itself is not shown as designated.
• Product-specific testing-coverage risk — medium: Tirzepatide has one Finnrick pass at 79.87%; Semaglutide, Retatrutide, Cagrilintide, Melanotan, Survodutide, Adipotide, Epitalon, and Liraglutide have no Finnrick record.
• Chain-of-custody and origin-verification risk — medium: Instagram evidence showed UK forwarding, the site used Hong Kong/mainland-China contact rails, field materials described an unlabeled vial, and no public batch-verification system was found.
• Payment-recourse risk — medium: The FAQ listed T/T, Western Union, Alipay, and Bitcoin; non-reversible rails reduce buyer recourse, especially with the domain offline.